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PASI: Psoriasis Area and Severity Index
Th1: T helper 1
Th: T helper
TNF: tumor necrosis factorINTRODUCTION
Granuloma annulare (GA) is a granulomatous
dermatosis characterized by dermal papules and
annular plaques. GA is thought to result from a T
helper (Th)1-mediated delayed-type hypersensitiv-
ity reaction, which elicits connective tissue degrada-
tion. A variety of events are thought to predispose to
GA, including trauma, diabetes, and medications.
Generalized GA can persist for decades despite
therapy and has a severe impact on quality of life.
In many cases, biological therapy is required to
achieve therapeutic success.1 Conversely, biologic
treatment for unrelated skin diseases such as psori-
asis have been suspected to trigger GA, in particular
antieinterleukin (IL)-17 antibodies.2,3
Here we describe a psoriasis patient who had
localized GA under apremilast treatment. Because of
inefficient control of psoriasis, therapy was switched
to secukinumab under which GA generalized. Both
psoriasis and GAwere then successfully treated with
adalimumab.
CASE REPORT
A 62-year-old man presented with a 20-year
history of severe plaque psoriasis (Fig 1, A). His
medical history was known to include metabolic
syndrome, such as diabetes. Previous conventional
topical and systemic psoriasis treatments were inef-
fective, leading to the introduction of apremilast
treatment. Shortly thereafter, limited annular plaques
developed on the dorsal side of the hands for the firstDepartment of Dermatology, Inselspital, Bern University
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dermatosis with deposition of mucin (Fig 1, C and
D). Thus, clinical presentation and histology were
consistent with GA, although other forms of drug-
induced granulomatous dermatitis could not be
ruled out completely. Topical treatment with clobe-
tasol propionate led to complete remission of GA
within weeks.
Eighteen months thereafter, his psoriasis wors-
ened despite continuous apremilast treatment. The
antipsoriatic therapy was, therefore, switched to
secukinumab, an antieIL-17 antibody, leading to a
rapid and sustained improvement of the psoriasis.
Psoriasis Area and Severity Index and Granuloma
Annulare Severity Index were the tools used to
measure the severity of the psoriasis and granuloma
annulare (Fig 2).4 However, 2 months later, the
patient had multiple annular, pruritic plaques on
the dorsal hands and distal arms (Fig 1, B), consistent
with a relapse and dissemination of GA. This time,
GA remained resistant to topical clobetasol propio-
nate treatment. Because secukinumab has beenJAAD Case Reports 2020;6:832-4.
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Fig 1. A, Severe plaque psoriasis before and after therapy. B, Generalized granuloma annulare
2 months after start with secukinumab. C, Hematoxylin-eosin staining of histology. D, mucin
stain of granulomatous skin lesions. E, Rapid improvement of erythematous and pruritic
component after treatment with adalimumab.
Fig 2. Timeline in relation to Psoriasis Area Severity Index
(PASI) and Granuloma Annulare Severity Index (GASI).
ADA, Adalimumab; APRE, apremilast; SECU, secukinumab.
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tinued. To therapeutically address both the psoriasis
and the extensive GA, therapy with adalimumab, a
tumor necrosis factor (TNF)-a inhibitor, was initi-
ated. Within 2 months, both the psoriasis and the
generalized GA showed an almost complete regres-
sion (Fig 1, C ). Adalimumab was well tolerated and
is currently being continued.DISCUSSION
Our case is in line with 2 previous reports of new-
onset of GA in association with antieIL-17 treat-
ment.2,3 It adds to these observations while also
presenting 2 novel features.
First, the de novo development of GA under
apremilast and the secondary exacerbation under
secukinumab suggest a pathomechanistic link be-
tween antipsoriatic drugs, especially those blockingthe Th17 pathway, and GA. Because both apremilast
and secukinumab mediate their antipsoriatic effects
via inhibition of the Th17 pathway, it can be specu-
lated that a disturbance of the balance between
different Th cell axes might be related to GA onset.5
In fact, reciprocal counter-regulation of the Th1 and
Th17 axes has been described; thus, blockade of IL-17
might enhance the activity of the Th1 axis and lead to
GA in predisposed individuals.6 Our patient suffered
frommetabolic syndrome and diabetes, both ofwhich
are considered predisposing risk factors for GA.7
Second, our case shows that the broad spectrum
of currently available immunomodulatory treatments
may allow us to select appropriate alternative drugs
that treat both the underlying psoriasis as well as the
treatment-associated GA. In our case, GA developed
under treatments inhibiting the Th17 pathway, thus
we chose a TNF-a inhibitor (adalimumab). Further,
TNF-a inhibition is a well-established treatment for
psoriasis, and up to 80% of patients with GA may
show a clinical response to TNF-a inhibition.1,8
Thus, TNF-a appears to have an integral role in the
pathogenesis of GA in addition to its known role in
psoriasis. To the best of our knowledge, this is the
first case report of a rapid successful treatment of
both plaque psoriasis and GA with the antieTNF-a
inhibitor, adalimumab.
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